Fibroblast Growth Factor 23 Impairs Phosphorus and Vitamin D Metabolism in Vivo and Suppresses 25-hydroxyvitamin D-1alpha-hydroxylase Expression in Vitro
Overview
Physiology
Affiliations
Fibroblast growth factor-23 (FGF-23) is critical to the pathogenesis of a distinct group of renal phosphate wasting disorders: tumor-induced osteomalacia, X-linked hypophosphatemia, and autosomal dominant and autosomal recessive hypophosphatemic rickets. Excess circulating FGF-23 is responsible for their major phenotypic features which include hypophosphatemia due to renal phosphate wasting and inappropriately low serum 1,25(OH)2D concentrations. To characterize the effects of FGF-23 on renal sodium-phosphate (Na/P(i)) cotransport and vitamin D metabolism, we administered FGF-23(R176Q) to normal mice. A single injection (0.33 microg/g body wt) induced significant hypophosphatemia, 20 and 29% decreases (P < 0.001) in brush-border membrane (BBM) Na/Pi cotransport at 5 and 17 h after injection, respectively, and comparable decreases in the abundance of type IIa Na/P(i) cotransporter protein in BBM. Multiple injections (6, 12, and 24 mug/day for 4 days) induced dose-dependent decreases (38, 63, and 75%, respectively) in renal abundance of 1alpha-hydroxylase mRNA (P < 0.05). To determine whether FGF-23(R176Q) exerts a direct action on 1alpha-hydroxylase gene expression, we examined its effects in cultured human (HKC-8) and mouse (MCT) renal proximal tubule cells. FGF-23(R176Q) (1 to 10 ng/ml) induced a dose-dependent decrease in 1alpha-hydroxylase mRNA with a maximum suppression of 37% (P < 0.05). Suppression was detectable after 6 h of exposure and maximal after 21 h. In MCT cells, FGF-23(R176Q) suppressed 1alpha-hydroxylase mRNA and activated the ERK1/2 signaling pathway. The MAPK inhibitor PD98059 effectively abolished FGF-23-induced suppression of 1alpha-hydroxylase mRNA by blocking signal transduction via ERK1/2. These novel findings provide evidence that FGF-23 directly regulates renal 1alpha-hydroxylase gene expression via activation of the ERK1/2 signaling pathway.
Evaluation of Bone Biomarkers in Renal Osteodystrophy.
Pichone A, Gomes C, Moreira C, Farias M, Leite Jr M Life (Basel). 2025; 14(12.
PMID: 39768249 PMC: 11679507. DOI: 10.3390/life14121540.
Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes.
An S, Nedumaran B, Oh H, Park T, Park C, Djalilian A BMB Rep. 2024; 57(12):533-538.
PMID: 39384178 PMC: 11693598.
Bowles S, Jacques R, Hill T, Eastell R, Walsh J Nutrients. 2024; 16(17).
PMID: 39275206 PMC: 11397043. DOI: 10.3390/nu16172888.
Xiao L, Clarke K, Hurley M Endocrinology. 2023; 164(12).
PMID: 37972265 PMC: 11032245. DOI: 10.1210/endocr/bqad173.
Tsai M, Jhou M, Liu T, Fang Y, Lu C Front Med (Lausanne). 2023; 10:1155426.
PMID: 37859858 PMC: 10582636. DOI: 10.3389/fmed.2023.1155426.